STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated news page for Abbott Laboratories (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbott Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbott Laboratories's position in the market.

Rhea-AI Summary
Abbott (NYSE: ABT) increases its quarterly common dividend by 7.8% to 55 cents per share, marking 52 years of consecutive dividend growth. The company will pay its 400th consecutive quarterly dividend since 1924 on Feb. 15, 2024. Abbott is a member of the S&P 500 Dividend Aristocrats Index, demonstrating its commitment to delivering strong shareholder returns and top-tier growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
dividends
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced the 36-month data from its TRANSCEND clinical trial, presenting the safety and efficacy of the SurVeil drug coated balloon (DCB) compared to the IN.PACT Admiral DCB for treating superficial femoral and proximal popliteal artery lesions. The primary efficacy and safety endpoints showed comparable outcomes, demonstrating the non-inferiority of the SurVeil DCB to the IN.PACT Admiral DCB. Dr. Peter A. Schneider presented the data at the 50th Annual VEITH Symposium in New York, New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced the 36-month data from its TRANSCEND clinical trial, presenting the safety and efficacy of the SurVeil drug coated balloon (DCB) compared to the IN.PACT Admiral DCB for treating superficial femoral and proximal popliteal artery lesions. The primary efficacy and safety endpoints showed comparable outcomes, demonstrating the non-inferiority of the SurVeil DCB to the IN.PACT Admiral DCB. Dr. Peter A. Schneider presented the data at the 50th Annual VEITH Symposium in New York, New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
Rhea-AI Summary
Abbott (NYSE: ABT) has announced new data from the ARIES trial, showing that advanced heart failure patients living with its HeartMate 3™ heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump. The trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. The ARIES trial also revealed cost-savings for heart failure patients who did not take aspirin following implant of an Abbott HeartMate 3 pump, with a 41% reduction in estimated costs related to bleeding events one year after receiving the device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
Rhea-AI Summary
Abbott (NYSE: ABT) study shows Healthy Food Rx program's positive impact on diabetes management and diet quality in Stockton, Calif.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Abbott announced 'Countdown at a Crossroads,' a campaign to raise awareness of diabetes and promote access to continuous glucose monitoring (CGM) systems. The campaign includes an animated installation at the Oculus Center in New York City featuring people impacted by diabetes. Every visit to www.Crossroads.Abbott in November triggers a donation to the American Diabetes Association's Health Equity Now program. Abbott aims to make CGM technology more accessible and affordable, as only 1% of adults with diabetes currently use it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary
Abbott has received FDA approval for its molecular HPV screening solution, expanding its Alinity m family of diagnostic assays. The test detects high-risk HPV infections that could lead to cancer and provides genotype determination on the 14 cancer-causing types of HPV. It is approved for use as a primary screen for cervical cancer and can be used in combination with a Pap test. The Alinity m HR HPV assay delivers information on five risk groups covering the 14 potentially cancer-causing genotypes, enabling physicians to assess the risk and tailor follow-up for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
fda approval
Rhea-AI Summary
Abbott (NYSE:ABT) has announced the launch of the Abbott HeartMates program, a new initiative aimed at creating a supportive community for people impacted by heart conditions. The program will provide emotional support, storytelling, and connection opportunities for participants. Professional football player Damar Hamlin will serve as the program's first ambassador. Heart disease affects over 100 million Americans, and the program aims to empower individuals to achieve their own comeback stories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

196.91B
1.72B
0.54%
77.05%
0.86%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
North Chicago

About ABT

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.